Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. OncologyPRO
  2. Meeting resources
  3. ESMO 2016

Impact of vitamin D3 replacement therapy on clinical outcomes and survival rates in patients with early stage breast cancer

Date

10 Oct 2016

Session

Poster display

Presenters

Ozan Yazici

Citation

Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364

Authors

O. Yazici1, S. Aksoy2, M.A. Sendur3, N. Ozdemir1, N. Zengin1, K. Altundag2

Author affiliations

  • 1 Medical Oncology, Ankara Numune Education and Research Hospital, 06100 - Ankara/TR
  • 2 Department Of Medical Oncology, Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 3 Department Of Medical Oncology, Ankara Ataturk Research and Teaching Hospital, Ankara/TR
More

Resources

Login

Abstract 2908

Background

In literature some studies suggested that in patients having solid malignancies poor prognosis is associated with vitamin D3 deficiency and replacement of vitamin D3 might have positive impact on prognosis. However, some of the results of the studies were against this suggestion. Therefore, in the current study we aimed to compare the clinical, pathological features and survival rates in patients with early breast cancer having regular vitamin D3 replacement or not.

Methods

In between October 2002 and October 2015, patients with early stage breast cancer were included in study population. The patients were divided into two groups according to their regular vitamin D3 replacement status. Vitamin D3 doses that the patients were receiving were calculated to increase the levels beyond 20 ng/mL (50 nmol/L). The patients with metastasis/relapse or second primary cancers were excluded.

Results

In vitamin D3 and non-vitamin D3 group 92 and 2864 patients were included. Median follow up time was 60 (min:1- max:420) months. Mean age at time of diagnosis, rate of patients with postmenopause, T1 tumor and breast conserving surgery was significantly higher in vitamin D3 replacement group compared with non-vitamin D3 group (p 

Conclusions

Regular vitamin D3 replacement therapy did not have effect on prognosis of patients with early breast cancer. Most of the postmenopausal and older aged patients with early breast cancer received vitamin D3 replacement most probably due to higher rate of osteoporosis in this aged patient group.

Clinical and pathological features of early breast cancer patients in vitamin D and non-vitamin D group

Regular Vitamin D Replacement Group (n = 92) (%) Non-Vitamin D Group (n = 2864) (%) p
Mean Age 59 ± 11 49 ± 13 0.001
Invasive Histopathological Subtype Dutal Lobular Other 75 5.4 19.6 70 5 25 0.77
Grade 1 2 3 21 45.2 33.9 13 44.9 42.1 0.14
Body Mass Index 0-25 kg/m2 25-29.9 kg/m2 ≥30 kg/m2 34.7 37.3 28 35.4 36.6 28.1 0.98
Menapausal Status Premenopausal Perimenopausal Postmenopausal 22.8 8.7 68.5 49.8 7.1 43.1 0.001
Breast Surgery Mastectomy Breast Conserving 52.2 46.4 65.7 33.8 0.04
Estrogen Receptor Positive Negative 83.3 16.7 75.2 24.8 0.11
Progesterone Receptor Positive Negative 77.8 22.2 71.4 28.6 0.23
Her-2 Status Positive Negative 13.3 86.7 19.4 80.6 0.18
TNM Tumor Stage T1 T2 T3 T4 55.6 31.9 9.7 2.8 34.8 48.8 13.6 2.8 0.004
TNM Nodal Stage N0 N1 N2 N3 54.1 29.7 8.1 5.4 46 27.3 12.5 9.5 0.37

Clinical trial identification

None

Legal entity responsible for the study

Ankara Numune Education and Research Hospital

Funding

None

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings